[1] DUMAN R S,AGHAJANIAN G K.Synaptic dysfunction in depression:potential therapeutic targets[J].Science,2012,338(6103):68-72.
[2] TRIVEDI M H,RUSH A J,WISNIEWSKI S R,et al.Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D:implications for clinical practice[J].Am J Psychiatry,2006,163(1):28-40.
[3] LARKIN G L,BEAUTRAIS A L.A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department[J].Int J Neuropsychopharmacol,2011,14(8):1127-1131.
[4] BERMAN R M,GAPPIELLO A,ANAND A,et al.Antidepressant effects of ketamine in depressed patients[J].Biol Psychiatry,2000,47(4):351-354.
[5] FUREY M L,DREVETS W C.Antidepressant efficacy of the antimuscarinic drug scopolamine:a randomized,placebo-controlled clinical trial[J].Arch Gen Psychiatry,2006,63(10):1121-1129.
[6] ABDALLAH C G,AVERILL L A,KRYSTAL J H.Ketamine as a promising prototype for a new generation of rapid-acting antidepressants[J].Ann N Y Acad Sci,2015,1344(5):66-77.
[7] RASMUSSEN K G,LINEBERRY T W,GALARDY C W,et al.Serial infusions of low-dose ketamine for major depression[J].J Psychopharmacol,2013,27(5):444-450.
[8] AANHETROT M,COLLINS K A,MURROUGH J W,et al.Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression[J].Biol Psychiatry,2010,67(2):139-145.
[9] ABDALLAH C G,FASULA M,KELMENDI B,et al.Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting[J].JECT,2012,28(3):157-161.
[10] DENK M C,REWERTS C,HOLSBOER F,et al.Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation[J].Am J Psychiatry,2011,168(7):751-752.
[11] DIAZGRANADOS N,IBRAHIM L A,BRUTSCHE N E,et al.Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder[J].J Clin Psychiatry,2010,71(12):1605-1611.
[12] NEWPORT D J,CARPENTER L L,MCDONALD W M,et al.Ketamine and other NMDA antagonists:early clinical trials and possible mechanisms in depression[J].Am J Psychiatry,2015,172(10):950-966.
[13] MCGIRR A,BERLIM M T,BOND D J,et al.A systematic review and meta-analysis of randomized,double-blind,placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes[J].Psychol Med,2015,45(4):693-704.
[14] ROMEO B,CHOUCHA W,FOSSATI P,et al.Meta-analysis of short-and mid-term efficacy of ketamine in unipolar and bipolar depression[J].Psychiatry Res,2015,230(2):682-688.
[15] MCEWEN B S.Physiology and neurobiology of stress and adaptation:central role of the brain[J].Physiol Rev,2007,87(3):873-904.
[16] SHANSKY R M,MORRISON J H.Stress-induceddendritic remodeling in the medial prefrontal cortex:effects of circuit,hormones and rest[J].Brain Res,2009,1293(10):108-113.
[17] MCEWEN B S.The ever-changing brain:cellular and molecular mechanisms for the effects of stressful experiences[J].Dev Neurobiol,2012,72(6):878-890.
[18] LI N,LEE B,LIU R J,et al.mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists[J].Science,2010,329(5994):959-964.
[19] MOGHADDAM B,ADAMS B,VERM A,et al.Activation of glutamatergic neurotransmission by ketamine:a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex[J].J Neurosci,1997,17(8):2921-2927.
[20] DUMAN R S,LI N,LIU R J,et al.Signaling pathways underlying the rapid antidepressant actions of ketamine[J].Neuropharmacology,2012,62(1):35-41.
[21] DWYER J M,DUMAN R S.Activation of mammalian target of rapamycin and synaptogenesis:role in the actions of rapid-acting antidepressants[J].Biol Psychiatry,2013,73(12):1189-1198.
[22] JEMIGAN C S,GOSWAMI D B,AUSTIN M C,et al.The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder[J].Prog Neuropsychopharmacol Biol Psychiatry,2011,35(7):1774-1779.
[23] HOEFFER C A,KLANN E.mTOR signaling:at the crossroads of plasticity,memory and disease[J].Trends Neurosci,2010,33(2):67-75.
[24] OTA K T,LIU R J,VOLETI B,et al.REDD1 is essential for stress-induced synaptic loss and depressive behavior[J].Nat Med,2014,20(5):531-535.
[25] CASTREN E,RANTAMAKTI T.The role of BDNF and its receptors in depression and antidepressant drug action:Reactivation of developmental plasticity[J].Dev Neurobiol,2010,70(5):289-297.
[26] DUNCAN W C,SARASSO S,FERRARELLI F,et al.Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder[J].Int J Neuropsychopharmacol,2013,16(2):301-311.
[27] HAILE C N,MURROUGH J W,IOSIFESCU D V,et al.Plasma brain derived neurotrophic factor(BDNF) and response to ketamine in treatment-resistantdepression[J].Int J Neuropsychopharmacol,2014,17(2):331-336.
[28] SANACORA G,SMITH M A,PATHAK S,et al.Lanicemine:a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects[J].Mol Psychiatry,2014,19(9):978-985.
[29] BURGDORF J,ZHANG X L,NICHOLSON K L,et al.GLYX-13,a NMDA receptor glycine-site functional partial agonist,induces antidepressant-like effects without ketamine-like side effects[J].Neuropsychopharmacology,2013,38(5):729-742.
[30] HOMAYOUN H,MOGHADDAM B.NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons[J].J Neurosci,2007,27(43):11496-11500.
[31] LIU R J,LEE F S,LI X Y,et al.Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex[J].Biol Psychiatry,2012,71(11):996-1005.
[32] SANACORA G,ZARATE C A,KRYSTAL J H,et al.Targeting the glutamatergic system to develop novel,improved therapeutics for mood disorders[J].Nat Rev Drug Discov,2008,7(5):426-437.
[33] DOUGHERTY L R,SMITH V C,BUFFERD S J,et al.Preschool irritability predicts child psychopathology,functional impairment,and service use at age nine[J].J Child Psychol Psychiatry,2015,56(9):999-1007.
[34] ZHOU W,WANG N,YANG C,et al.Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex[J].Eur Psychiatry,2014,29(7):419-423.
[35] KOIKE H,CHAKI S.Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats[J].Behav Brain Res,2014,271:111-115.
[36] JOURDI H,HSU Y T,ZHOU M,et al.Positive AMPA receptor modulation rapidly stimulates BDNF release and increases dendritic mRNA translation[J].J Neurosci,2009,29(27):8688-8697.
[37] OHISHI H,OGAWA-MEGURO R,SHIGEMOTO R,et al.Immunohistochemical localization of metabotropic glutamate receptors,mGluR2 and mGluR3,in rat cerebellar cortex[J].Neuron,1994,13(1):55-66.
[38] FUREY M L,KHANNA A,HOFFMAN E M,et al.Scopolamine produces larger antidepressant and antianxiety effects in women than in men[J].Neuropsychopharmacology,2010,35(12):2479-2488.
[39] VOLETI B,NAVARRIA A,LIU R J M,et al.Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling,synaptogenesis,and antidepressant behavioral responses[J].Biol Psychiatry,2013,74(10):742-749. |
